TrialPloS one2014

[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.

Mammar Hachemi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.